|
|
PYGM |
glycogen phosphorylase, muscle associated |
- Glycogen breakdown (glycogenolysis)
- Glycogen breakdown (glycogenolysis)
|
- Pyridoxal phosphate
- Beta-D-Glucopyranose Spirohydantoin
- (5S,7R,8S,9S,10R)-3-Amino-8,9,10-trihydroxy-7-(hydroxymethyl)-6-oxa-1,3-diazaspiro[4.5]decane-2,4-dione
- alpha-D-glucose 6-phosphate
- N-beta-D-glucopyranosylacetamide
- Monofluorophosphate ion
- Beta-D-Glucose
- 3,8,9,10-tetrahydroxy-7-hydroxymethyl-6-oxa-1,3-diaza-spiro[4.5]decane-2,4-dione
- Nojirimycine Tetrazole
- Indirubin-5-sulphonate
- 2-Deoxy-Glucose-6-Phosphate
- C-(1-hydrogyl-beta-D-glucopyranosyl) formamide
- alpha-D-glucopyranosyl-2-carboxylic acid amide
- alpha-D-glucose-1-phosphate
- 8,9,10-Trihydroxy-7-hydroxymethyl-2-thioxo-6-oxa-1,3-diaza-spiro[4.5]decan-4-one
- 4-{2,4-Bis[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid
- 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,2,3-Benzimidazole
- N-acetyl-N'-beta-D-glucopyranosyl urea
- 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Benzothiazole
- C-(1-Azido-Alpha-D-Glucopyranosyl) Formamide
- 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Oxadiazole
- CP-320626
- (3,4,5-Trihydroxy-6-Hydroxymethyl-Tetrahydro-Pyran-2-Yl)-Phosphoramidic Acid Dimethyl Ester
- 8,9,10-trihydroxy-7-hydroxymethyl-3-methyl-6-oxa-1,3-diaza-spiro[4.5]decane-2,4-dione
- Alvocidib
- 1-deoxy-1-methoxycarbamido-beta-D-glucopyranose
- N-[(5S,7R,8S,9S,10R)-8,9,10-Trihydroxy-7-(hydroxymethyl)-2,4-dioxo-6-oxa-1,3-diazaspiro[4.5]dec-3-yl]acetamide
- 1-Deoxy-1-methoxycarbamido-beta-D-gluco-2-heptulopyranosonamide
- 4-{2-[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid
- 2,3-Dicarboxy-4-(2-Chloro-Phenyl)-1-Ethyl-5-Isopropoxycarbonyl-6-Methyl-Pyridinium
- N(6)-(pyridoxal phosphate)-L-lysine
- Heptulose-2-Phosphate
- N-(Benzoylcarbamoyl)-beta-D-glucopyranosylamine
- Dexfosfoserine
- 1-Deoxy-1-acetylamino-beta-D-gluco-2-heptulopyranosonamide
- Inosinic Acid
- 7-{2,6-DICHLORO-4-[3-(2-CHLORO-BENZOYL)-UREIDO]-PHENOXY}-HEPTANOIC ACID
- 4-{3-CHLORO-4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-PHENOXY}-BUTYRIC ACID
- 4-{4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2,3-DIMETHYL-PHENOXY}-BUTYRIC ACID
- 5-{3-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2-METHYL-PHENOXY}-PENTANOIC ACID
- 2-CHLORO-N-[(1R,2R)-1-HYDROXY-2,3-DIHYDRO-1H-INDEN-2-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE
- 2-CHLORO-N-[(3R)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE
- (S)-2-CHLORO-N-(1-(2-(2-HYDROXYETHYLAMINO)-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL)-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE
- (2S)-N-[(3S)-1-(2-AMINO-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-2-CHLORO-2H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE
- (3R,4R,5R)-5-(HYDROXYMETHYL)-1-(3-PHENYLPROPYL)PIPERIDINE-3,4-DIOL
- ({[(3E)-2'-Oxo-2',7'-dihydro-2,3'-biindol-3(7H)-ylidene]amino}oxy)acetic acid
- (5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-phenyl-1,6-dioxa-2-azaspiro[4.5]dec-2-ene-8,9,10-triol
- 2-DEOXY-3,4-BIS-O-[3-(4-HYDROXYPHENYL)PROPANOYL]-L-THREO-PENTARIC ACID
- (3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(2-naphthyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol
- (3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(4-methylphenyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol
|
- Glycogen storage diseases (GSD), including: von Gierke disease (GSD type Ia); Pompe disease (GSD type II); Cori disease, Forbe disease (GSD type III); Andersen disease (GSD type IV); McArdle disease (GSD type V); Hers disease (GSD type VI); Tarui disease (GSD type VII); Phosphorylase kinase deficiency (GSD type IX); Fanconi-Bickel syndrome (GSD type XI); Glycogen synthase deficiency (GSD type 0)
|